
- /
- Supported exchanges
- / F
- / I25.F
iRhythm Technologies Inc (I25 F) stock market data APIs
iRhythm Technologies Inc Financial Data Overview
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get iRhythm Technologies Inc data using free add-ons & libraries
Get iRhythm Technologies Inc Fundamental Data
iRhythm Technologies Inc Fundamental data includes:
- Net Revenue: 619 M
- EBITDA: -58 414 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-01
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
iRhythm Technologies Inc News

IRTC Q1 Earnings Call: Outperformance Driven by Zio AT and Primary Care Channel Expansion
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results topping the market’s revenue expectations , with sales up 20.3% year on year to $158.7 million. The company�...


2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COV...

Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ResMed (NYSE:RMD) and the best and worst ...

Why iRhythm Technologies (IRTC) Is Among the Best Performing Healthcare Stocks to Buy Now
We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where iRhythm Technologies, Inc. (NASDAQ:IRTC) stands against other bes...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.